Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AbbVie Inc. or Twist Bioscience Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how AbbVie Inc. and Twist Bioscience Corporation compare based on key financial metrics to determine which better meets your investment needs.

About AbbVie Inc. and Twist Bioscience Corporation

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Latest Biotechnology and AbbVie Inc., Twist Bioscience Corporation Stock News

As of September 21, 2026, AbbVie Inc. had a $467.4 billion market capitalization, compared to the Biotechnology median of $269.5 million. AbbVie Inc.’s stock is up 15.8% in 2026, up 1% in the previous five trading days and up 19.14% in the past year.

Currently, AbbVie Inc.’s price-earnings ratio is 74.7. AbbVie Inc.’s trailing 12-month revenue is $64.4 billion with a 9.8% net profit margin. Year-over-year quarterly sales growth most recently was 10.2%. Analysts expect adjusted earnings to reach $14.011 per share for the current fiscal year. AbbVie Inc. currently has a 2.6% dividend yield.

As of September 21, 2026, Twist Bioscience Corporation had a $10.4 billion market cap, putting it in the 78th percentile of all stocks. Twist Bioscience Corporation’s stock is up 422.8% in 2026, up 23.1% in the previous five trading days and up 493.31% in the past year.

Currently, Twist Bioscience Corporation does not have a price-earnings ratio. Twist Bioscience Corporation’s trailing 12-month revenue is $431.8 million with a -31.7% net profit margin. Year-over-year quarterly sales growth most recently was 23.2%. Analysts expect adjusted earnings to reach $-0.600 per share for the current fiscal year. Twist Bioscience Corporation does not currently pay a dividend.

How We Compare AbbVie Inc. and Twist Bioscience Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AbbVie Inc. and Twist Bioscience Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

AbbVie Inc. and Twist Bioscience Corporation Stock Value Grades

Company	Ticker	Value
AbbVie Inc.	ABBV	F
Twist Bioscience Corporation	TWST	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

AbbVie Inc. has a Value Score of 16, which is Ultra Expensive. Twist Bioscience Corporation has a Value Score of 4, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither AbbVie Inc. or Twist Bioscience Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if AbbVie Inc. or Twist Bioscience Corporation is the better investment when it comes to value.

AbbVie Inc. and Twist Bioscience Corporation’s Momentum Grades

Company	Ticker	Momentum
AbbVie Inc.	ABBV	B
Twist Bioscience Corporation	TWST	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

AbbVie Inc. has a Momentum Score of 65, which is Strong. Twist Bioscience Corporation has a Momentum Score of 99, which is Very Strong.

The Momentum Grade Winner: Twist Bioscience Corporation

As you can clearly see from the Momentum Grade breakdown above, Twist Bioscience Corporation is considered to have stronger momentum compared to AbbVie Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Twist Bioscience Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AbbVie Inc. and Twist Bioscience Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
AbbVie Inc.	ABBV	D
Twist Bioscience Corporation	TWST	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

AbbVie Inc. has a Earnings Estimate Score of 32, which is Negative. Twist Bioscience Corporation has a Earnings Estimate Score of 38, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither AbbVie Inc. or Twist Bioscience Corporation has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if AbbVie Inc. or Twist Bioscience Corporation is the better investment when it comes to estimate revisions.

Other AbbVie Inc. and Twist Bioscience Corporation Grades

In addition to Estimate Revisions, Value and Momentum, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AbbVie Inc. and Twist Bioscience Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, AbbVie Inc. or Twist Bioscience Corporation Stock?

Overall, AbbVie Inc. stock has a Value Score of 16, Momentum Score of 65 and Estimate Revisions Score of 32.

Twist Bioscience Corporation stock has a Value Score of 4, Momentum Score of 99 and Estimate Revisions Score of 38.

Comparing AbbVie Inc. and Twist Bioscience Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.